| P2093 | author name string | Mary Chester M Wasko | |
| | Xiaoqin Tang | |
| | Lisa L Schroeder | |
| | Androniki Bili | |
| P2860 | cites work | Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis | Q24801010 |
| | Effects of torcetrapib in patients at high risk for coronary events | Q29619609 |
| | Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis | Q33687843 |
| | Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis | Q34182804 |
| | The mortality of rheumatoid arthritis | Q34338843 |
| | High-density lipoprotein as a therapeutic target: a systematic review | Q34663242 |
| | Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease | Q34684331 |
| | Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies | Q34889152 |
| | Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study | Q34897630 |
| | Effects of extended-release niacin with laropiprant in high-risk patients | Q35205560 |
| | Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis | Q35553035 |
| | Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis | Q35954510 |
| | Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. | Q36190844 |
| | Low high-density lipoprotein cholesterol: an important consideration in coronary heart disease risk assessment | Q37100823 |
| | Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease | Q37859679 |
| | Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm | Q38115132 |
| | Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment | Q41913088 |
| | Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids | Q41943371 |
| | Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? | Q43255462 |
| | Corticosteroid therapy increases HDL-cholesterol concentrations in patients with active sarcoidosis and hypoalphalipoproteinemia | Q43975797 |
| | Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. | Q44123361 |
| | Glucocorticoids and insulin sensitivity in rheumatoid arthritis | Q44881615 |
| | Effect of glucocorticoids on the arteries in rheumatoid arthritis | Q45184227 |
| | Insulin resistance and impaired beta cell function in rheumatoid arthritis | Q46161578 |
| | High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy | Q46329867 |
| | Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance. | Q54389817 |
| | Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. | Q55047291 |
| | Dyslipidaemia in Rheumatoid Arthritis: The Role of Inflammation, Drugs, Lifestyle and Genetic Factors | Q57751173 |
| | Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study | Q58160099 |
| | Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. I. Relativity to inflammatory activity | Q69439079 |
| | Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men | Q73023474 |
| | Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis | Q74169414 |
| | High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors | Q77406810 |
| | Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years | Q78794833 |
| | Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study | Q79850163 |
| | Rheumatoid arthritis and cardiovascular disease | Q82076745 |
| | Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor α therapy | Q85042756 |
| P433 | issue | 6 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 1059-1067 | |
| P577 | publication date | 2014-12-25 | |
| P1433 | published in | Rheumatology International | Q15763689 |
| P1476 | title | Glucocorticoid use is associated with increase in HDL and no change in other lipids in rheumatoid arthritis patients. | |
| P478 | volume | 35 | |